January 30, 2017 6:01pm
Sector stocks on Monday descended significantly after three positive <Friday, Wednesday and Tuesday> closes and two negative <Thursday and last Monday> closes last week
These advance/decline line “clods” and share pricing “divots” are worrisome; there are signs that the sector may see further downturn.
Pre-open indication’s tally: 4 hit (BLUE, BSTG, CLBS and OSIR) and 1 miss (AGTC)
I answer one question; in which company should investors put, keep and commit their money!
… As I focus on the facts in evidence …
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
U.S. equities fell on Monday as a new measure taken by the Trump administration on immigration gave investors pause, with energy lagging.
The NASDAQ closed DOWN -47.07 or 09.83% to 5613.71 and the DOW closed DOWN -174.63 or -0.87% to 19,919.15.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was negative with an A/DL of 11/28 and 4 flats;
- The mid-day slipped negative with an A/DL of 8/30 and 5 flats;
- The close stayed negative with an A/DL of 9/28 and 6 flats;
Henry’omics:
From the mid-day’s investor’s letter, “the discounts on the past few offerings are more than onerous and there are more financings to come.”
- As I had stated, “What and why are we buying from those who have only delivered losses and depreciated share pricing for years...”
Some companies are also ignoring the rules of disclosure, management “failures” of executive “actions and performance” thus affecting the way their platforms and pre-clinical results are presented!
- As an “evaluator” who serves investors, I offer warning analysis, analysis of quarterly results that invariably crash under the strain of spending and attempts of some management teams to manipulate perception of development platforms!
From Friday’s newsletter, “Athersys’ (ATHX) offering’s pricing is an OMEN for those in the queue of capital market access!”
- Monday’s decline could be a harbinger of more weakness ahead as quarterly results from Q4/16 have yet to appear!
Doubts about Q1/17 tend to garner more taunts than catcalls, which are starting to significantly erode any momentum.
- Fear is a factor … while the CBOE Volatility Index (VIX) – the fear index of +12.3% tend to imply complacency by the market while those of 20 indicate that the market is betting on a swing in prices to occur sooner than later. Remember, “bears” bite …
Indexes, the ebb and flow:
- The iShares Russell 2000 (IWM) indicated a negative -0.70% in the pre- open and closed DOWN -1.40%.
- The iShares NASDAQ Biotechnology (IBB) indicated a negative -0.51% in the pre-open and closed DOWN -1.35%
Pre-open indication’s tally: 4 hit (BLUE, BSTG, CLBS and OSIR) and 1 miss (AGTC)
- Applied Genetic Technologies (AGTC) closed DOWN -$0.75 – miss;
- Biostage (BSTG) closed UP +$0.0153 – hit;
- bluebird bio (BLUE) closed DOWN -$2.50 – hit;
- Caladrius Biosciences (CLBS) closed DOWN -$0.30 – hit;
- Osiris (OSIR) closed DOWN -$0.31 – hit;
Today’s 5 top dollar gainers included:
- Kite Pharma (KITE) +$0.30 after Friday’s -$0.32;
- uniQure (QURE) -$0.14;
- Histogenics (HSGX) +$0.05 after Friday’s FLAT at $1.54;
- BioLife Solutions (BLFS) +$0.06;
- ImmunoCellular (NYSEMKT: IMUC) +$0.03
Today’s 5 largest dollar losers of the session were:
- bluebird bio (BLUE) -$2.50 after Friday’s +$2.65 after Thursday’s +$0.65;
- Regenxbio (RGNX) -$1.70;
- Spark Therapeutics (ONCE) -$0.99 after Friday’s +$1.47 after Thursday’s -$0.53 after Wednesday’s +$0.76 after last Monday’s +$0.39;
- Cellectis SA (CLLS) -$0.83;
- Applied Genetic Technologies (AGTC) -$0.75 after Friday’s FLAT at $8.15;
Flat:
- Aduro Biotech (ADRO) at $11.15;
- Cytori (CYTX) at $1.59;
- Fate Therapeutics (FATE) at $2.78;
- ReNeuron (RENE.L) at $2.45
- Microbot (MBOT formerly STEM) at $1.28;
- Sangamo (SGMO) at $3.55;
The downside trend reflects a pricing trend range of:
- Monday’s decliners ranged from -0.34% <KOOL> to -9.20% <AGTC> in 28 equities;
- Friday’s decliners ranged from -0.32% <VTGN> to -26.32% <ATHX> in 18 equities;
- Thursday’s decliners ranged from -0.02% <KITE> to -6.45% <AST> in 24 equities;
- Wednesday’s decliners ranged from -0.30% <BTX> to -7.444% <IMUC> in 12 equities;
- Tuesday’s decliners ranged from -0.44% <CAPR> to -3.57% <AGTC> in 15 equities;
- Last Monday’s decliners ranged from -0.08% <BLUE> to -10.46% <FATE> in 25 equities;
The upside shows a pricing trend range of:
- Monday’s gainers ranged from +0.00% <VTGN> to +3.29% <HSGX> in 9 equities;
- Friday’s gainers ranged from +0.25% <RGNX> to +12.77% <CLBS> in 23 equities;
- Thursday’s gainers ranged from +0.17% <MESO> to +4.95% <NWBO> in 14 equities;
- Wednesday’s gainers ranged from +0.22% <ONCE> to +10.49% <FCSC> in 28 equities;
- Tuesday’s gainers ranged from +0.35% <KOOL> to +14.78% <IMUC> in 26 equities;
- Last Monday’s gainers ranged from +0.55% <ONCE> to +5.07% <KOOL> in 13 equities;
The week’s beginning:
- Monday’s 9 gainers followed Friday’s 23, Thursday’s 14, Wednesday’s 28, Tuesday’s 26 and last Monday’s 13
- Monday’s 28 decliners followed Friday’s 18, Thursday’s 24, Wednesday’s 12, Tuesday’s 15 and last Monday’s 25
Review my fear gauge or the CBOE Volatility Index (VIX):
· Monday traded near 12.3 – +16.5% higher;
· Friday traded near 10.5;
· Thursday traded near 10.9;
· Wednesday traded near 10.8;
· Tuesday traded near 11.4;
· Last Monday traded near 12.2;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
